(Reuters) -Eli Lilly hit $1 trillion in market value on Friday, making it the first drugmaker to enter the exclusive club dominated by tech giants and underscoring its rise as a weight-loss powerhouse.
Here are some reactions to Lilly joining the trillion dollar club:
EVAN SEIGERMAN, ANALYST AT BMO CAPITAL MARKETS
"The current valuation points to investor confidence in the longer-term durability of the company's metabolic health franchise. It also suggests that investors prefer Lilly over Novo in the obesity arms race. Taking a step back, we're also seeing money rotate into the sector as investors may be worried about an AI bubble."
HANK SMITH, DIRECTOR & HEAD OF INVESTMENT STRATEGY AT LILLY SHAREHOLDER HAVERFORD TRUST
"Investors have historically liked secure earnings growth and (Eli Lilly) is the only large cap pharma that has that kind of earnings profile."
(Reporting by Siddhi Mahatole and Shashwat Chauhan in Bengaluru; Editing by Leroy Leo)
LATEST POSTS
- 1
Tesla plans to expand production at German car plant - 2US EPA will reassess safety of herbicide paraquat, says its chief
- 3Little Italy Mercato brings fresh food and community to downtown San Diego
- 4Anti-war protests held across Israel under wartime gathering limits
- 5How to Build a Yard That Helps Monarchs During Spring Migration
- Corcept Therapeutics shares surge as lead drug gets FDA nod for ovarian cancer
- Which Brilliant Home Gadget Can't You Reside Without?
- Sean Penn lights up, Kylie Jenner gets A-list approval and 7 other moments you didn’t see at the Golden Globes
- Pick Your #1 Kind Of Bread
- The Best 15 Applications for Efficiency and Association
- Glamour Shots once ruled the mall. I went to one of the last ones standing.
- South America's Memorable Destinations: A Movement Guide
- 4 astronauts depart ISS, leaving behind just 3 crewmates to staff the orbiting lab
- First SpaceX booster for upgraded Starship fails during test in Texas
